AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00556387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Study NCT00556387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Study NCT00646633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture and patient education
Description: Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
Study NCT02083354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
Study NCT02083354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study NCT04684888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax Femto-flap
Description: Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards.
Study NCT04684888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sub Bowman's keratomileusis (SBK)-flap
Description: Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~.
Study NCT01679314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore device
Description: Each study group will go under the same treatment regimen and assessments.
Study NCT01679314 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore device
Description: Each study group will go under the same treatment regimen and assessments.
Study NCT01615120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 125 mg
Description: One 125 mg tablet once a day
Study NCT01615120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758 250 mg
Description: two 125 mg tablets once daily
Study NCT03706755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine: 1mcg/kg
Description: intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Study NCT03706755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 0,5mcg/kg
Description: intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
Study NCT03614650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered immune cells
Description: Engineered immune effector cells (EIE)
Study NCT02869152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of 99mTc-sulfur colloid
Description: Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
Study NCT03737474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
Study NCT03080428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genomic test
Description: genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
Study NCT02869152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of ICG
Description: Dye injection around the rectal tumor for SLN mapping with NIR imaging.
Study NCT02869152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Spot
Description: Dye injection for tattooing rectal tumor prior to surgical resection.
Study NCT02869152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Description: Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
Study NCT02869152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic NIR imaging and gamma probe
Description: Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
Study NCT02869152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dissection of sentinel lymph node(s)
Description: Surgical removal of identified lymph nodes in the rectum.
Study NCT00648609 — intervention group
Intervention type: OTHER
Intervention: Palliative home care in advanced COPD
Description: Interdisciplinary palliative care team on community based self care management of advanced COPD.
Study NCT00648609 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Usual care for COPD patients
Study NCT01798043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later
Study NCT01798043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with and without pacemaker stimulation
Description: Patient is undergoing a Cardiac MRI at enrollment and 12 months later
Study NCT03682419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VKA Patients
Description: Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
Study NCT03682419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-VKA Patients
Description: Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
Study NCT04395976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
Study NCT01167075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin Original
Study NCT01167075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intestamin plus Fresubin Original
Study NCT01314313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation with SAPIEN XT
Description: Operable Group with SAPIEN XT
Study NCT01314313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR Implantation
Description: Control Group
Study NCT00830882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosalbutamol
Description: 2 puffs four times a day for 2 weeks
Study NCT00830882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic salbutamol
Description: 2 puffs four times a day for 2 weeks
Study NCT00830882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 puffs four times a day for 2 weeks
Study NCT00796939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green light mask
Description: Participants will receive approximately 10,000 lux from green light-emitting diodes.
Study NCT00796939 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Red Light Mask
Description: Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
Study NCT01213888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trientine Hydrochloride
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
Study NCT01213888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo capsules
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
Study NCT00836693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 5 milligrams (mg) administered orally once a day for 12 weeks
Study NCT00836693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet administered orally once a day for 12 weeks.
Study NCT04195763 — intervention group
Intervention type: DRUG
Intervention: asfotase alfa
Description: This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
Study NCT03098875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia using sevoflurane as a hypnotic agent
Study NCT03098875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia using propofol as a hypnotic agent
Study NCT03098875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: General anesthesia using remifentanil as an analgesic.
Study NCT00578539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA C
Description: Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
Study NCT00578539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
Study NCT00578539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
Study NCT00578539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
Study NCT00578539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath-1h
Description: CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
Study NCT00578539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells are infused on day 0
Study NCT01125592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IonCLeanse Footbath
Description: Application of an ionic footbath for 30 minutes per week for 4 weeks
Study NCT04718077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraosseus
Description: IO dexamethasone injection Dexamethasone 4 mg
Study NCT04718077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Submucoal
Description: SM dexamethasone injection Dexamethasone 4 mg
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: given during Rapid COJEC and modified N7 therapy
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: given during Rapid COJEC and modified N7 therapy
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ch14.18/CHO
Description: ch14.18/CHO antibody is given during MRD treatment
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO
Description: ch14.18/CHO antibody is given during MRD treatment
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is given during Induction Treatment (R3 arm modified N7)
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is given during Induction Treatment
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan is given during MAT treatment
Study NCT01704716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is given during MAT treatment
Study NCT02231086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant HIPEC (open/laparoscopic)
Description: Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
Study NCT02231086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard adjuvant systemic chemotherapy
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
Study NCT02231086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant systemic chemotherapy
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
Study NCT02231086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
Study NCT02231086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic laparoscopy
Description: Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
Study NCT03780244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic 8ml
Description: Treatment of nasolabial folds
Study NCT03780244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra Aesthetic 5ml
Description: Treatment of nasolabial folds
Study NCT01222052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Description: Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
Study NCT01222052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
Description: Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks
Study NCT02389296 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be distributed to nursing staff
Study NCT02946723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Lead implantation surgery for SNM using ultrasound guided technique
Study NCT02946723 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: X-ray
Description: Lead implantation surgery for SNM using X-ray technique
Study NCT01695226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: pre-operative celecoxib (400 mg) twice daily for two to three weeks
Study NCT01695226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pre-operative placebo twice daily for two to three weeks
Study NCT04424134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine and Spironolactone
Description: Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
Study NCT04424134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base therapy
Description: Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
Study NCT01323114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic duodenal exclusion
Description: Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
Study NCT01323114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Treatment
Description: Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
Study NCT00169897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (teaching and exercise)
Description: After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.